HER2-Positive Breast Cancer | Clinical

DESTINY-Breast03 Update Reinforces Safety of Trastuzumab Deruxtecan in Metastatic Breast Cancer

June 04, 2022

A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer

Sacituzumab Govitecan Sustains Efficacy Across HER2 Expressions in TNBC

May 06, 2022

Metastatic triple-negative breast cancer appears to derive clinical benefit from sacituzumab govitecan-hziy overtime, regardless of patients’ HER2 expression, according to a post hoc analysis of the phase 3 ASCENT trial.